Answers are grounded in this paper and cite their sources.
Retrospective analysis demonstrates trametinib's effectiveness in pediatric LCH, suggesting a safer dosing strategy.
Background Langerhans cell histiocytosis (LCH) is a rare malignancy driven by MAPK pathway activation and often involves BRAF V600E mutations. Targeted therapy with trametinib, a MEK inhibitor, is a promising alternative to conventional chemotherapy. Procedure We retrospectively analyzed the records of patients treated with trametinib either at relapse or as front‐line therapy between 2020 and 2024. Results Fifteen pediatric patients received trametinib either at diagnosis ( n = 6), relapse ( n = 7), or due to chemotherapy intolerance ( n = 2). Molecular testing identified MAPK pathway mutations in 11 patients. The median age at treatment initiation was 5 years (range: 0.1–16.5). Notably, five of these patients started trametinib before the age of 1. The median treatment duration was 2.2 years (range: 0.1–4.7 years). All 15 patients achieved favorable responses without concerns regarding growth and development. The adverse effects included rash (40%) and diarrhea (13%), which were all mild and were managed with temporary dose adjustments. A self‐weaning dosing strategy minimized long‐term exposure while maintaining disease control. Conclusion Our data suggest that trametinib is a safe and effective therapy for pediatric LCH with broad efficacy and tolerability. However, prospective studies are needed to confirm these findings and refine targeted treatment protocols.
No takes yet. Share an insight, caveat, or question.
Wojciechowska et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: